[printfriendly]
December 2013—Myriad Genetics launched a new prognostic test, Myriad myPlan Lung Cancer, for patients diagnosed with early stage lung adenocarcinoma. MyPlan Lung Cancer is an RNA expression panel of 31 cell-cycle-progression genes in combination with tumor staging information to determine a patient’s risk of dying from lung cancer within five years.
The myPlan Lung Cancer test has been extensively studied in more than 1,500 patients. In these studies, the test was shown to be significantly predictive of five-year lung cancer mortality and considerably more predictive than tumor staging information alone.
“Post-surgical treatment decisions for early stage lung cancer patients are largely guided by tumor staging. However, the prognostic power of tumor stage alone is limited and there remain unacceptably high mortality rates for this patient population,” Mark C. Capone, president of Myriad Genetics Laboratories, said in a statement. “Myriad myPlan Lung Cancer is a powerful new prognostic test that stratifies patients based on their risk of lung cancer-related, five-year mortality. Our test will empower physicians to know with confidence which patients should receive surgery alone versus those who may need more aggressive therapy.”
Myriad myPlan Lung Cancer is being launched in a phased approach beginning with an early access, clinical-experience program to medical and scientific thought leaders, followed by a full commercial launch in 2014.
Myriad Genetics, 800-469-7423